Age at Onset | Age at Death | Pathology Diagnosis | APOE | Braak Stage | Thal Phase | CERAD Score | IHC | Biochem | |
---|---|---|---|---|---|---|---|---|---|
LBD | |||||||||
Case 1 | 71 | 81 | LBD/AD/CAA | ε3/ε3 | V-VI | 5 | C3 | A, C, M | – |
Case 2 | 60 | 68 | LBD/AD/CAA | ε3/ε4 | VI | 5 | C3 | A, C, M | C |
Case 3 | 70 | 83 | LBD/AD | ε3/ε4 | VI | 5 | C3 | A, C, M | – |
Case 4 | 70 | 80 | LBD/AD | ε3/ε3 | III | 3 | C2 | A, C, M | – |
Case 5 | 73 | 80 | LBD/AD | ε3/ε4 | VI | 5 | C3 | A, C, M | MTL |
Case 6 | 51 | 62 | LBD/AD | ε3/ε3 | II | 5 | C3 | A, C, M | – |
Case 7 | 63 | 67 | LBD/AD | ε3/ε4 | III | 4 | C3 | A, C, M | A, MTL |
Case 8 | 62 | 67 | LBD/AD | ε3/ε4 | III | 3 | C1 | A, C, M | – |
Case 9 | 84 | 90 | LBD/AD | ε3/ε3 | III | 5 | C2 | A, C, M | – |
Case 10 | 67 | 72 | LBD/AD | ε2/ε3 | V-VI | 3 | C2 | – | C |
Case 11 | 59 | 66 | LBD/AD/CAA | ε3/ε4 | IV | 2 | C3 | – | C |
Case 12 | 40 | 78 | LBD/AD/CAA | ε3/ε3 | IV | 3 | C3 | – | MTL |
Case 13 | 64 | 74 | LBD/AD/CAA | ε2/ε4 | VI | 5 | C2 | – | MTL |
Case 14 | 62 | 68 | LBD/AD | ε4/ε4 | V | 3 | C3 | – | MTL |
AD/ALB | |||||||||
Case 15 | (> 90) | (> 90) | AD/CAA | ε2/ε3 | V-VI | 3 | C3 | A, C, M | – |
Case 16 | – | 82 | AD | ε2/ε3 | III | 3 | C1 | A, C, M | – |
Case 17 | 58 | 63 | AD | ε3/ε3 | VI | 3 | C3 | A, C, M | – |
Case 18 | 75 | 83 | AD/CAA | ε3/ε4 | V | 3 | C2 | A, C, M | – |
Case 19 | 62 | 77 | AD/PSP | – | II | 3 | C2 | A, C, M | – |
Case 20 | 57 | 64 | AD/CAA | ε3/ε3 | V | 5 | C3 | A, C, M | MTL |
Case 21 | 40 | 77 | AD/CAA | ε2/ε3 | II | 2 | C2 | A, C, M | MTL |
Case 22 | (> 90) | (> 90) | AD/CAA | ε3/ε3 | VI | 4 | C3 | A, C, M | – |
Case 23 | 53 | 67 | AD | ε3/ε3 | VI | 3 | C3 | A, C, M | – |
Controls | |||||||||
Case 24 | – | 87 | No neurological diagnosis | ε2/ε3 | 0 | 0 | 0 | – | MTL |
Case 25 | 56 | 67 | FTLD-TDP | ε3/ε3 | 0 | 0 | 0 | – | MTL |
Case 26 | – | 82 | Cerebrovascular arteriolosclerosis | ε2/ε3 | II | 2 | C1 | – | C |
Case 27 | – | 52 | No neurological diagnosis | ε3/ε4 | II | 2 | C1 | – | C |